美国商业新闻2006年6月19日佛罗里达州科科纳特河消息——

RespCare有限公司（RespCare, Inc.）今天宣布推出突破性的Hybrid（TM）通用持续气道正压通气（CPAP）界面装置。Hybrid（TM）界面独特，融合了鼻枕和口腔界面，可望满足大多数阻塞性睡眠呼吸暂停（OSA）患者的需求。

该公司已与一家财富1000强企业的医疗部门签订了全球独家分销协议。RespCare公司预计，该产品五年内可为公司带来超过$1亿美元的收入。公司在全球范围申请了10多项与此产品相关的专利。公司还宣称，这款新产品适合危重病护理和长期护理环境，可用于无创通气（NIV），代表着一个规模巨大的成长型市场。

持续气道正压通气（CPAP）治疗法用于治疗睡眠呼吸紊乱（SDB）；据估计，约有2000万美国人患有这种病症。2005年，持续气道正压通气（CAPP）界面装置的全球市场规模超过$5亿美元，并以每年20－25％的速度增长。该领域其它企业包括：ResMed有限公司（纽约证券交易所：RMD）、Respironics有限公司（纳斯达克股票代码：RESP）、费雪帕克医疗保健有限公司（Fisher & Paykel Healthcare，新西兰证券交易所：FPH，澳大利亚证券交易所：FPH）以及泰科国际有限公司（Tyco International Ltd，纽约证券交易所：TYC）旗下的主要业务部门泰科保健公司（Tyco Healthcare）。

在佛罗里达州博卡拉顿的“博卡拉顿睡眠中心”进行的滴定研究已证实，该治疗设备品质优异，将为睡眠实验室技术人员与呼吸病治疗人员选择界面产品提供更大的余地。

博卡拉顿睡眠中心的Natalio J. Chediak博士说，“能够参与测试一项新的界面装置，我们感到非常兴奋。这款混合型产品丰富了全面部界面产品的种类。如许多技术人员反映的那样，口腔泄漏是治疗性睡眠研究中最难解决的副作用，在患者后续临床诊治过程中，这一问题一直存在。解决这个问题的过程中，湿化技术发挥了一定的作用，但副作用并没有完全根除。”

Chediak博士补充说，“RespCare公司新型全面罩以通用界面，重新带来舒适和多功能的概念。我们的技术人员和患者发现， Hybrid（TM）产品提供了多种鼻腔插管和口腔垫尺寸，佩戴起来非常容易，这种面罩应用广泛，便于家庭使用。”

他还表示，“此外，Hybrid（TM）是一款全新设计的面罩，不会阻挡视线，这样病人在睡觉之前还能看书，完全避免了传统的全面罩常见的前额或鼻梁擦伤现象。护罩快速托扣装置以及软管分离装置与其它全面罩界面一样符合标准。总而言之，从全面罩可选产品的意义来说，Hybrid（TM）用起来就像‘呼吸新鲜空气’一样。”

关于RespCare有限公司

RespCare有限公司（RespCare, Inc.）总部位于佛罗里达州科科纳特河，属Mergenet 解决方案有限公司（Mergenet Solutions，Inc）全资所有。RespCare公司致力于产品的开发、商业化、制造和营销，其产品用以治疗阻塞性睡眠呼吸暂停（OSA）及其它呼吸紊乱型疾病。其姐妹企业，InnoMed科技有限公司（InnoMed Technologies, Inc.）于2002年完成产品开发，推出创新型Nasal-Aire持续气道正压通气（CPAP）界面装置，2年内即赢得10％的市场份额，该产品成为全球阻塞性睡眠呼吸暂停（OSA）和无创通气（NIV）市场广泛认可的持续气道正压通气（CPAP）界面产品，并一直保持市场优势。欲知更多有关Hybrid（TM）界面产品的信息，请访问： www.hybridmask.com 。

联系方式：RespCare有限公司 Elizabeth Kelley Grace，561-989-9855 手机：561-702-7471 lizkgrace@aol.com

(BW)(FL-RESPCARE) RespCare Introduces the Revolutionary Hybrid(TM) Sleep Therapy Device

COCONUT CREEK, Fla.--(BUSINESS WIRE)--June 19, 2006--

RespCare, Inc. announced today that it has launched its revolutionary Hybrid(TM) Universal CPAP interface. The Hybrid(TM) interface has a unique combination of nasal pillows with an oral interface and is expected to become the interface of choice for the majority of obstructive sleep apnea (OSA) patients.

The company has signed an exclusive global distribution agreement with the medical division of a Fortune 1000 company. RespCare expects revenues in the excess of $100 million over a five year period from the sale of this product. The company has filed over 10 patents globally related to this product. The company also states that there is a large and growing market for the new device for non-invasive ventilation (NIV) in critical care and long term care environments.

Continuous Positive Airway Pressure (CPAP) therapy is used to treat sleep-disordered breathing (SDB), which is estimated to affect approximately 20 million Americans. The global market for CPAP interfaces exceeded $500 million in 2005 and is growing at 20 - 25% a year. Other companies in this space include ResMed Inc. (NYSE:RMD), Respironics, Inc. (Nasdaq:RESP), Fisher & Paykel Healthcare (NZSX: FPH, ASX: FPH) and Tyco Healthcare, a major business segment of Tyco International Ltd (NYSE:TYC).

Titration studies performed at Boca Raton Sleep Center in Boca Raton, FL have confirmed that this therapy will be an excellent interface of choice for sleep lab technicians and respiratory therapists.

"Being involved in the trial of a new interface was exciting for us, but the hybrid brings a new meaning to Full Face Interface options. Oral leaks are one of the most difficult side effects one can encounter during a therapeutic sleep study (as reported by many technologists) but an ongoing problem on follow up visits in the clinic for the life span of the patient. Humidification has been helpful in part battling this problem but not the complete picture", said Dr. Natalio J. Chediak, who is associated with Boca Raton Sleep Center.

"RespCare's new family line of Full Face masks has brought back the meaning of comfort and versatility in a universal interface. Our technologists and patients found fitting the Hybrid(TM) to be a simple task and with the different nasal insert and oral cushion sizes, this mask is versatile in its application and for use at home," Dr. Chediak added.

He went on to say, "Additionally, the Hybrid(TM) brings a totally new mask, with un-obstructive view so patients can read before bedtime and eliminate any of the fore-head or bridge of the nose abrasions that one sees with traditional Full Face masks. The quick trap release and hose disconnect are standard as with other FFM interfaces. In summary, the Hybrid(TM) is like a 'breath of fresh air' to the meaning of FFM options."

About RespCare, Inc.

RespCare, Inc., headquartered in Coconut Creek, Fl is a wholly owned subsidiary of Mergenet Solutions, Inc and is engaged in developing, commercializing, manufacturing and marketing products to treat obstructive sleep apnea (OSA) and other respiratory disorders. Its sister company, InnoMed Technologies, Inc. developed and launched the revolutionary Nasal-Aire CPAP interface in 2002 that captured 10% market share within 2 years and continues to be a widely accepted CPAP interface in the worldwide OSA and non-invasive ventilation (NIV) markets. More information on the Hybrid(TM) interface can be found at www.hybridmask.com

CONTACT: RespCare, Inc. Elizabeth Kelley Grace, 561-989-9855 cell: 561-702-7471 lizkgrace@aol.com